23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future

Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million

Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs